J.P. Morgan Retains "Neutral" Rating On Biogen Idec (BIIB)

In a research report released by J.P. Morgan JPM, the firm reiterated their Neutral rating on shares of Biogen Idec BIIB. JPM has a price target of $55.00 on the stock. During the current trading session, BIIB shares have gained 1.18% to $47.92. Biogen Idec Inc. (BIIB) is a global biotechnology company. The products of the Company include AVONEX, RITUXAN, TYSABRI and FUMADERM. The Company’s products address diseases, such as multiple sclerosis (MS), non-Hodgkin’s lymphoma (NHL), rheumatoid arthritis (RA), Crohn’s disease (CD) and psoriasis.